TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1680247

Group type: EXPERIMENTAL
Intervention: Sulphasalazine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Mesalazine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: In vitro preincubation with sulphasalazine and mesalazine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 9
Study: 6849209

Group type: EXPERIMENTAL
Intervention: Metronidazole + Gentamicin (M + G)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Clindamycin + Gentamicin (C + G)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Metronidazole (M)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Clindamycin (C)
Number of subjects: 141
Study: 30818068

Group type: EXPERIMENTAL
Intervention: Thymus preservation (TP)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Bilateral thymectomy (BT)
Number of subjects: 54
Study: 29980333

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg/0.05 ml)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation (PRP)
Number of subjects: 328
Study: 27814737

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg daily for 3 months)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (lactose monohydrate, daily for 3 months)
Number of subjects: 80
Study: 24443804

Group type: EXPERIMENTAL
Intervention: Intra-articular hyaluronic acid (IA-HA) injection once a week for five weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Oral non-steroidal anti-inflammatory drugs (NSAIDs) three times per day for five weeks
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intra-articular hyaluronic acid (IA-HA) injection
Number of subjects: 200
Study: 22448872

Group type: EXPERIMENTAL
Intervention: exercise + vitamin D (800 IU/d)
Number of subjects: 409

Group type: COMPARATOR
Intervention: exercise + placebo
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: no exercise + vitamin D (800 IU/d)
Number of subjects: 409

Group type: COMPARATOR
Intervention: no exercise + placebo
Number of subjects: 409
Study: 19282413

Group type: EXPERIMENTAL
Intervention: Night splinting
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Nerve gliding
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control
Number of subjects: 70
Study: 17190624

Group type: EXPERIMENTAL
Intervention: Avoidance measures
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Contact allergens (positive test)
Number of subjects: 121
Study: 16038476

Group type: EXPERIMENTAL
Intervention: tenofovir+didanosine+efavirenz (arm C)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: tenofovir+lamivudine+efavirenz (arm B)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: zidovudine+lamivudine+lopinavir/ritonavir (arm A)
Number of subjects: 28
Study: 11929758

Group type: EXPERIMENTAL
Intervention: Factor V Leiden
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: APC resistance
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: HR2 haplotype homozygosity
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: HR2 haplotype (carriers)
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: Double heterozygotes for HR2 and factor V Leiden
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: High factor V antigen plus factor V Leiden
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: Factor V antigen
Number of subjects: 1023
Study: 9464212

Group type: EXPERIMENTAL
Intervention: CCK‐4 (N = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (N = 15)
Number of subjects: 30
Study: 7659436

Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory (BDI)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: External psychological measures and selected questionnaire items
Number of subjects: 247
Study: 2766083

Group type: EXPERIMENTAL
Intervention: Eye movement perimetry with Octopus perimeter
Number of subjects: 23
Study: 795608

Group type: EXPERIMENTAL
Intervention: Once-daily tablet preparation containing 1.5 mg fluphenazine plus 30 mg nortriptyline taken at night
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Once-daily tablet preparation containing 1.5 mg fluphenazine plus 30 mg nortriptyline taken in the morning
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Three drug schemes including 1 tablet t.d.s. (three times daily)
Number of subjects: 223
Study: 31295907

Group type: EXPERIMENTAL
Intervention: MyMAFI mobile application
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard paper-based format
Number of subjects: 36
Study: 28938966

Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 1415

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 1415
Study: 25372450

Group type: EXPERIMENTAL
Intervention: Purse-string suture
Number of subjects: 44

Group type: COMPARATOR
Intervention: Second intention healing
Number of subjects: 44
Study: 24280466

Group type: EXPERIMENTAL
Intervention: Conventional Western medicine plus Bu‐Fei Jian‐Pi granules, Bu‐Fei Yi‐Shen granules, and Yi‐Qi Zi‐Shen granules
Number of subjects: 352

Group type: COMPARATOR
Intervention: Conventional Western medicine
Number of subjects: 352
Study: 21685187

Group type: EXPERIMENTAL
Intervention: SNPs near the HLA region on chromosome 6p21 and in an intergenic region on chromosome 2q21
Number of subjects: 3441

Group type: EXPERIMENTAL
Intervention: Candidate SNPs within cholinergic receptors, nicotinic, alpha 3/5 (CHRNA3/CHRNA5)
Number of subjects: 3441

Group type: EXPERIMENTAL
Intervention: Candidate SNP CYP2A6
Number of subjects: 3441

Group type: EXPERIMENTAL
Intervention: Candidate SNP rs3025343 in DBH
Number of subjects: 3441
Study: 19297141

Group type: EXPERIMENTAL
Intervention: Ciclesonide 800mcg twice daily (starting with 800mcg hourly for 3h after randomization)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Prednisolone 40mg once daily for 2 weeks
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Ciclesonide
Number of subjects: 130

Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 130
Study: 16806614

Group type: EXPERIMENTAL
Intervention: Maximal voluntary contractions (Strength)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Fatigue test to exhaustion
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Electromyographic indices of fatigue
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Electromyographic indices of neuromuscular activation patterns
Number of subjects: 31
Study: 14872449

Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 16094787

Group type: EXPERIMENTAL
Intervention: Concept mapping
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no concept mapping)
Number of subjects: 0
Study: 10487800

Group type: EXPERIMENTAL
Intervention: Lovastatin (33 mg/day)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Usual care (diet)
Number of subjects: 199
Study: 7745018

Group type: EXPERIMENTAL
Intervention: GHRP-1 (1 microgram/kg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: GHRH (1 microgram/kg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: GHRP-1 and GHRH together
Number of subjects: 22
Study: 1691811

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by radiotherapy (arm A)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Alternating chemotherapy and radiotherapy (arm B)
Number of subjects: 116
Study: 31254455

Group type: EXPERIMENTAL
Intervention: Aerobic exercise session combined with abdominal radiofrequency
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo group (0 Watt radiofrequency)
Number of subjects: 30
Study: 30058347

Group type: EXPERIMENTAL
Intervention: REL (traditional method)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: TT (talk test method)
Number of subjects: 28

Group type: COMPARATOR
Intervention: NEG (TT)
Number of subjects: 28
Study: 27631396

Group type: EXPERIMENTAL
Intervention: Exercise intervention (aerobic and muscle strength training, 3 sessions per week for 19 ± 2 weeks)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study: 25649967

Group type: EXPERIMENTAL
Intervention: Provider advice on weight gain during pregnancy
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Advice meeting Institute of Medicine recommendations
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Concordance of mothers' personal weight gain target with clinical recommendations
Number of subjects: 123
Study: 24271696

Group type: EXPERIMENTAL
Intervention: Wide nervous resection
Number of subjects: 350

Group type: COMPARATOR
Intervention: Simple section or minimal resection
Number of subjects: 350
Study: 21922138

Group type: EXPERIMENTAL
Intervention: 100 mg of recombinant human lactoferrin (bLf) twice a day for one month
Number of subjects: 21

Group type: COMPARATOR
Intervention: 520 mg of ferrous sulfate once a day
Number of subjects: 21
Study: 19304862

Group type: EXPERIMENTAL
Intervention: 15 mg escitalopram
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 17591659

Group type: EXPERIMENTAL
Intervention: Ketamine 0.27 mg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ketamine 0.081 mg/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 12
Study: 16671337

Group type: EXPERIMENTAL
Intervention: Benazepril (10-20 mg/day) or Imidapril (5-10 mg/day) for 6 weeks
Number of subjects: 509
Study: 12200950

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia with propofol and remifentanil (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Spinal block with bupivacaine 0.5% hyperbaric solution 10 mg (n = 20)
Number of subjects: 40
Study: 9537306

Group type: EXPERIMENTAL
Intervention: Black tea (600 mls, 50.7 mg flavonoids)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Black tea (126.8 mg flavonoids)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Coffee (control)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Black tea and coffee consumption
Number of subjects: 15
Study: 7634515

Group type: EXPERIMENTAL
Intervention: Gentamicin 4 mg/kg q24h iv
Number of subjects: 126

Group type: COMPARATOR
Intervention: Netilmicin 5.5 mg/kg q24h iv
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 126
Study: 2695513

Group type: EXPERIMENTAL
Intervention: Sucralfate (SUC)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cimetidine (CIM)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 80
Study: 31100353

Group type: EXPERIMENTAL
Intervention: Primary IOL treatment in unilaterally affected eyes (pre-IATS)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Primary IOL treatment in unilaterally affected eyes (post-IATS)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Primary IOL treatment in bilaterally affected eyes (pre-IATS)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Primary IOL treatment in bilaterally affected eyes (post-IATS)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Year-wise calculation of primary IOL treatment
Number of subjects: 183
Study: 28092325

Group type: EXPERIMENTAL
Intervention: Opioid analgesics
Number of subjects: 948

Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 948
Study: 25638526

Group type: EXPERIMENTAL
Intervention: C-IMRT treatment
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Mean dose to BOT
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Mean doses to BOT, OC, and VP
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 34
Study: 23957255

Group type: EXPERIMENTAL
Intervention: Multifactorial risk factor intervention program
Number of subjects: 195

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 195
Study: 22348833

Group type: EXPERIMENTAL
Intervention: 3-day omeprazole administration
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: 3-day famotidine administration
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: 1-day famotidine and then 2-day omeprazole administration
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Overall success rate for endoscopic hemostasis
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 116
Study: 19687332

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Everolimus 70 mg weekly
Number of subjects: 30
Study: 17606174

Group type: EXPERIMENTAL
Intervention: Herbal medicine trials
Number of subjects: 89

Group type: COMPARATOR
Intervention: Conventional medicine trials
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Both groups (Herbal and Conventional)
Number of subjects: 89
Study: 15013994

Group type: EXPERIMENTAL
Intervention: Weck-Cel sponge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultracell sponge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Merocel sponge
Number of subjects: 0
Study: 12779186

Group type: EXPERIMENTAL
Intervention: Group therapy plus education
Number of subjects: 64

Group type: COMPARATOR
Intervention: Education alone
Number of subjects: 64
Study: 9598952

Group type: EXPERIMENTAL
Intervention: Extra-amniotic prostaglandin F2alpha
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intracervical misoprostol
Number of subjects: 40
Study: 7517156

Group type: EXPERIMENTAL
Intervention: Videotape education
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Nurse education
Number of subjects: 217

Group type: COMPARATOR
Intervention: Control group (usual written material)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Videotape education and Nurse education
Number of subjects: 217
Study: 2686710

Group type: EXPERIMENTAL
Intervention: Nifedipine (mean dose 43 +/- 16 mg daily) added to HCTZ (50 mg daily)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 9
Study: 990353

Group type: COMPARATOR
Intervention: No somatic controls
Number of subjects: 60

Group type: COMPARATOR
Intervention: RR pacing
Number of subjects: 60

Group type: COMPARATOR
Intervention: EMG feedback
Number of subjects: 60

Group type: COMPARATOR
Intervention: RR pacing plus EMG feedback
Number of subjects: 60
Study: 30663474

Group type: EXPERIMENTAL
Intervention: Person-centred group intervention (4 weeks of group intervention and a follow-up home visit)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 131
Study: 31254526

Group type: EXPERIMENTAL
Intervention: Combined delivery (cesarean delivery for twin B)
Number of subjects: 842
Study: 28239984

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR‐NTX) for 25 weeks
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR‐NTX) for 78 weeks
Number of subjects: 308

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR‐NTX)
Number of subjects: 308
Study: 26521574

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) applied to specific acupuncture points, once a day, 5 times a week, for 8 weeks.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional rehabilitation training and medication (Control group).
Number of subjects: 60
Study: 23157209

Group type: EXPERIMENTAL
Intervention: Continuous Training Group (CTG)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Intermittent Training Group (ITG)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 49
Study: 21684489

Group type: EXPERIMENTAL
Intervention: Motor retraining program (3 additional 30-minute sessions per week for 6 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard inpatient rehabilitation
Number of subjects: 32
Study: 18690279

Group type: EXPERIMENTAL
Intervention: Acute LBP patients
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chronic LBP patients
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison between acute and chronic LBP patients
Number of subjects: 60

Group type: COMPARATOR
Intervention: SIA, LSA, SHA, total and segmental lordosis angles
Number of subjects: 60
Study: 16150263

Group type: EXPERIMENTAL
Intervention: Amnioreduction
Number of subjects: 73

Group type: COMPARATOR
Intervention: Septostomy
Number of subjects: 73
Study: 12394995

Group type: EXPERIMENTAL
Intervention: Percutaneous electrical nerve stimulation
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Number of subjects: 133

Group type: COMPARATOR
Intervention: Medication only
Number of subjects: 133
Study: 9934936

Group type: EXPERIMENTAL
Intervention: Half-cycle sertraline dosing
Number of subjects: 31

Group type: COMPARATOR
Intervention: Full-cycle sertraline dosing
Number of subjects: 31
Study: 7776527

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine 1.5 mg.kg‐1 2 minutes before laryngoscopy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl 4 micrograms.kg‐1
Number of subjects: 36

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 36
Study: 2157364

Group type: EXPERIMENTAL
Intervention: Cisplatin and vindesine
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Cisplatin, vindesine and mitomycin C
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Cisplatin and etoposide alternating with vindesine and mitomycin C
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Cisplatin, vindesine and mitomycin combination regimen
Number of subjects: 199
Study: 74352

Group type: EXPERIMENTAL
Intervention: (+)-cyanidanol-3 (1.5g daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: azathioprine (100mg daily)
Number of subjects: 16
Study: 29059340

Group type: EXPERIMENTAL
Intervention: Pictorial warnings
Number of subjects: 2149

Group type: COMPARATOR
Intervention: Text-only warnings
Number of subjects: 2149
Study: 26120075

Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection (80 U subcutaneously)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous methylprednisolone (1 g daily for 5 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study: 24722826

Group type: EXPERIMENTAL
Intervention: Higher SF-36 mental health composite scores
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: Friends' encouragement for exercise
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: Friends' encouragement for healthy eating
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: Perceived stress and select health-related quality of life indices
Number of subjects: 1025
Study: 23890767

Group type: EXPERIMENTAL
Intervention: Viscum album [L.] extract (VaL) therapy
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Viscum album [L.] extract (VaL) therapy in 'good' prognosis subgroup
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Viscum album [L.] extract (VaL) therapy in 'poor' prognosis subgroup
Number of subjects: 220

Group type: COMPARATOR
Intervention: No antineoplastic therapy (control)
Number of subjects: 220

Group type: COMPARATOR
Intervention: No antineoplastic therapy (control) in 'good' prognosis subgroup
Number of subjects: 220

Group type: COMPARATOR
Intervention: No antineoplastic therapy (control) in 'poor' prognosis subgroup
Number of subjects: 220
Study: 20843746

Group type: EXPERIMENTAL
Intervention: 150μg corifollitropin alfa
Number of subjects: 1509

Group type: COMPARATOR
Intervention: 200IU rFSH
Number of subjects: 1509
Study: 19031498

Group type: EXPERIMENTAL
Intervention: Behavioral Training (BT)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Waitlist-control group
Number of subjects: 95
Study: 16318613

Group type: EXPERIMENTAL
Intervention: Cervical dilation
Number of subjects: 131

Group type: COMPARATOR
Intervention: No cervical dilation (Control)
Number of subjects: 131
Study: 12651862

Group type: EXPERIMENTAL
Intervention: Moderate-volume training (30 min/session, 6 sessions/week for 8 weeks)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: High-volume training (60 min/session, 6 sessions/week for 8 weeks)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Moderate-volume training
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: High-volume training
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study: 10861116

Group type: EXPERIMENTAL
Intervention: Ligustrazine plus propranolol
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 74
Study: 9104903

Group type: EXPERIMENTAL
Intervention: Aspirin 200 mg/day, ticlopidine 500 mg/day, and warfarin for 1 month (group 1)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Aspirin and ticlopidine (group 2)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Aspirin alone (group 3)
Number of subjects: 275
Study: 8286878

Group type: EXPERIMENTAL
Intervention: Hypocaloric glucose alone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hypocaloric glucose with amino acids
Number of subjects: 20
Study: 3816876

Group type: EXPERIMENTAL
Intervention: Once-a-day dosing (15 mg metaclazepam in the evening)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Twice-a-day dosing (5 mg in the morning plus 10 mg in the evening)
Number of subjects: 12
Study: 29340679

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (n = 107)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Laparoscopic Roux-en-Y gastric bypass (n = 110)
Number of subjects: 217
Study: 26691837

Group type: EXPERIMENTAL
Intervention: DMB-3111 (6 mg/kg, single intravenous infusion over 90 min)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Trastuzumab (6 mg/kg, single intravenous infusion over 90 min)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: DMB-3111
Number of subjects: 70

Group type: COMPARATOR
Intervention: Trastuzumab
Number of subjects: 70
Study: 23568674

Group type: EXPERIMENTAL
Intervention: Trapeziectomy with ligament reconstruction and tendon interposition (LRTI)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Simple trapeziectomy
Number of subjects: 54
Study: 21813569

Group type: EXPERIMENTAL
Intervention: Transfer into an open cot at 1600 g
Number of subjects: 182

Group type: COMPARATOR
Intervention: Transfer into an open cot at 1800 g
Number of subjects: 182
Study: 20157081

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Both ranitidine and diphenhydramine
Number of subjects: 98

Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 98